ライフサイエンスコーパス: treatment protocol

1 col) or after ileitis was fully established (treatment protocol).

2 and the outcome of our prospectively applied treatment protocol.

3 d tissue injury was minimal using a clinical treatment protocol.

4 Tests and models were stratified by treatment protocol.

5 Fifteen patients completed the treatment protocol.

6 treatment, 90 (74%) completed the specified treatment protocol.

7 olone, remained active when tested in a post-treatment protocol.

8 se rates using a fixed-interval rituximab re-treatment protocol.

9 th baseline clinical characteristics but not treatment protocol.

10 lant sites, with the appropriate recommended treatment protocol.

11 are being used more frequently as part of a treatment protocol.

12 ecologic Oncology Group randomized phase III treatment protocol.

13 n should be considered within the CAR T-cell treatment protocol.

14 her IM862 or EMAP-II was included in the PDT treatment protocol.

15 ystem (CNS) relapse, with stratification for treatment protocol.

16 identify the toxicities associated with this treatment protocol.

17 uride or insulin according to an intensified treatment protocol.

18 phy in a dose-dependent manner over a 14-day treatment protocol.

19 including certain antioxidant agents in the treatment protocol.

20 varying treatment parameters to optimize the treatment protocol.

21 pproach using ranibizumab and details of the treatment protocol.

22 ny significant benefit, independently of the treatment protocol.

23 ormally establish the merits of our proposed treatment protocol.

24 mes were not compromised by adherence to the treatment protocol.

25 of complication-free tumour under different treatment protocols.

26 next generation TMS devices, experiments and treatment protocols.

27 e preservation using two different xenograft treatment protocols.

28 nerves was the main difference between the 2 treatment protocols.

29 ent of rigorous science-based diagnostic and treatment protocols.

30 administered by oral gavage on prevention or treatment protocols.

31 k of uniform patient populations and varying treatment protocols.

32 ehavior, prognosis, and response to specific treatment protocols.

33 g to current Children's Oncology Group (COG) treatment protocols.

34 gests that survival is improving with modern treatment protocols.

35 gnostics could improve future diagnostic and treatment protocols.

36 and pulmonary support were titrated based on treatment protocols.

37 avenous saline and insulin, similar to human treatment protocols.

38 treatment of uterine leiomyomas by using two treatment protocols.

39 ideration of material properties in devising treatment protocols.

40 ow the physicians to plan for more effective treatment protocols.

41 clinical trials and its inclusion in future treatment protocols.

42 evelopment of standardized multiple-modality treatment protocols.

43 re studies are needed that compare different treatment protocols.

44 and clinical toxicity associated with these treatment protocols.

45 terations and respond poorly to conventional treatment protocols.

46 ferential diagnosis and test the efficacy of treatment protocols.

47 e degree of lung inflammation and cumbersome treatment protocols.

48 water or water alone in either prevention or treatment protocols.

49 help in the development and optimization of treatment protocols.

50 o Pediatric Oncology Group Hodgkin's disease treatment protocols.

51 the possibility of developing individualized treatment protocols.

52 appeared to be similar in both of the L-NAME treatment protocols.

53 pressive disorder enrolled in 6 standardized treatment protocols.

54 cardiac dose/volume and should guide future treatment protocols.

55 lications for designing effective antibiotic treatment protocols.

56 ntensive BP-lowering or standard BP-lowering treatment protocols.

57 essive treatment according to graft-specific treatment protocols.

58 onsideration when contemplating prophylactic treatment protocols.

59 strength to resin cement than other surface treatment protocols.

60 ical analyses for identifying robust optimal treatment protocols.

61 herapy and the development of more efficient treatment protocols.

62 timulation parameters for effective and safe treatment protocols.

63 these individuals do not respond to current treatment protocols.

64 treatment options, and to establish optimal treatment protocols.

65 ey are most likely to be cured with standard treatment protocols.

66 rats were given the following during a 2-wk treatment protocol: (1) candesartan cilexetil (AT1 recep

67 uction of peritransplantation rituximab into treatment protocols (4 of 62 immunotherapy recipients co

68 les of high-dose methotrexate in St Jude ALL treatment protocols; a combined meta-analysis yields a P

69 line by emergency physicians, not reflecting treatment protocols according to the current guidelines.

70 objective evaluation of the effectiveness of treatment protocols, accuracy of staging and restaging m

71 Strikingly, in the treatment protocol administration of soluble VWAK and FY

72 Patients treated with standardized treatment protocol after cardiac arrest.

73 accrual of older persons to phase II and III treatment protocols after study initiation compared with

74 ting for other known risk factors, including treatment protocol, age, white blood cell count, DNA ind

75 By logistic regression with treatment, protocol, age, and gender as covariates, fema

76 Following treatment protocols, all rats underwent hyperinsulinemic

77 each) received combinations of the following treatment protocols: ALS, 0.5 ml on days -1 and 2; BM, 2

78 independent core laboratories blinded to the treatment protocol analyzed the angiographic and intrava

79 Seventy-one patients entered the transplant treatment protocol and 38 underwent liver transplantatio

80 Firstly, we established an acute treatment protocol and demonstrated this protocol could

81 tified analyses were performed to adjust for treatment protocol and known risk factors, and in the mo

82 There was no association between treatment protocol and response trajectory.

83 ion, markedly extending survival in an early-treatment protocol and significantly though transiently

84 bility of clinical oncologists to design new treatment protocols and analyze the response of patients

85 roenvironment with the potential to optimize treatment protocols and evaluate synergies between tumor

86 lications for designing effective antibiotic treatment protocols and for assessing the risks of antib

87 he potential to significantly improve trauma-treatment protocols and outcomes in hospital and prehosp

88 dy, which may lead to improved diagnosis and treatment protocols and reduce the incidence of acute bi

89 he COURAGE trial by nurse case managers with treatment protocols and resulted in significant improvem

90 e results may inform future childhood cancer treatment protocols and SMN surveillance guidelines for

91 have highlighted the interaction of specific treatment protocols and the immune environment on outcom

92 otherapy for food allergy requires prolonged treatment protocols and, in most cases, does not lead to

93 ge III retinoblastoma treated with a uniform treatment protocol, and as far as the authors are aware,

94 lled study inclusion and exclusion criteria, treatment protocol, and surveillance requirements, with

95 the emergence of viral resistance, demanding treatment protocols, and adverse side effects have expos

96 cohort study to characterise global surgical treatment protocols, and assess surgical outcomes, compl

97 and severities of acute toxic effects across treatment protocols, and facilitate international resear

98 relation to trial arm, comorbid conditions, treatment protocols, and metastatic versus localized dis

99 Patients were not followed with uniform treatment protocols, and only limited information about

100 elarus and will enable improved diagnostics, treatment protocols, and prognostic decision-making.

101 medical contact-to-device time, coordinated treatment protocols, and regional data collection and re

102 us, as well as clinical practice guidelines, treatment protocols, and reimbursement policies.

103 in children, information regarding standard treatment protocols, and survival outcomes.

104 lammatory disease, carefully follow accepted treatment protocols, and teach youth comprehensive sexua

105 d to be used within the context of a defined treatment protocol; and f) no monitoring device, no matt

106 , and differences in severity of disease and treatment protocols; and measurement of different clinic

107 contexts including the study design details, treatment protocols, animal characteristics and conventi

108 The traumatic grief treatment protocol appears to be a promising interventio

109 Our current treatment protocol appears to be associated with favorab

110 This treatment protocol appears to be feasible and safe in me

111 Despite different treatment protocols applied to patients and use of diffe

112 le, well-described diagnostic guidelines and treatment protocols are essential: but often lacking.

113 inconclusive for many approaches, and clear treatment protocols are not available.

114 In current radiation oncology practice, treatment protocols are prescribed based on the average

115 blishment and validation of hypoxia-directed treatment protocols are still under development, and it

116 e diagnosis of NPD and the evaluation of NPD treatment protocols, as well as for the study of ceramid

117 e observed that a 24 h 100 uM Mn restoration treatment protocol attenuated an established HD 'cargo-r

118 Patients were randomized to treatment protocol based on intracranial pressure plus b

119 idualized screening, genetic counseling, and treatment protocols based on patient ethnicity and race

120 ervention group did not begin their assigned treatment protocol because of withdrawal of consent and

121 our DNA in patients assigned to one of three treatment protocols between May 8, 1993, and June 6, 201

122 nes are used in over 50% of childhood cancer treatment protocols, but their clinical usefulness is li

123 Individual changes of the treatment protocol by face-to-face communication between

124 ad of skin carcinomas, however, the chemical treatment protocol caused ulcerous skin lesions, and 89%

125 these observations, we designed an improved treatment protocol combining plasmonic nanoantennae with

126 iatric oncologists have developed aggressive treatment protocols, combining surgery, craniospinal rad

127 Treatment protocol consisted of reduction of immunosuppr

128 Treatment protocol consisted of reduction of immunosuppr

129 ive assessable patients were enrolled onto a treatment protocol consisting of dexamethasone-containin

130 re studies of rats performed using a similar treatment protocol demonstrated greater reduction of glo

131 ell injection, whether using a prevention or treatment protocol design.

132 This MS-275 treatment protocol did not result in a redistribution of

133 The TNFalpha treatment protocols did not appear to produce any toxici

134 Two animals in the hypotensive treatment protocols died during the second and third ble

135 Mice in all treatment protocols displayed decreased vascular permeab

136 The modified treatment protocol effectively and safely prevented graf

137 n PA-treated rats, demonstrating that the PA treatment protocol effectively lowered ET-1 biosynthesis

138 ricted that even small changes in lesions or treatment protocols eliminate benefit, then the variabil

139 development pipelines, and biomarker-defined treatment protocols enabling personalization of medicine

140 Particularly in the late treatment protocol, ethyl gallate resulted in a lower he

141 are activated by the use of two distinctive treatment protocols followed by selective CO adsorption

142 The aim of this study was to develop a treatment protocol for (225)Ac-PSMA-617 alpha-radiation

143 uality evidence supporting a community-based treatment protocol for children with severe acute malnut

144 2 days postinfection, simulating a potential treatment protocol for DENV infection in humans.

145 ion and primary care, and incorporation of a treatment protocol for hospital services.

146 lation chemotherapy has been a long-standing treatment protocol for human neoplasia.

147 a novel non-invasive and non-pharmacological treatment protocol for neuropathic pain management, was

148 A treatment protocol for the use of pulmonary artery cathe

149 Current treatment protocols for (177)Lu-labeled PSMA-617 therapi

150 drug target selection and the development of treatment protocols for a molecularly targeted therapy.

151 larabine, and provide rationales for current treatment protocols for both T-ALL and T-lymphoblastic l

152 rent burn patients and to establish standard treatment protocols for burn pain.

153 odies have become incorporated into standard treatment protocols for cancer.

154 Doses used were based on optimized treatment protocols for each agent individually.

155 sions and to develop specific assessment and treatment protocols for each particular problem.

156 ent, there are no standardized diagnostic or treatment protocols for EATL.

157 nd to improve our prevention, diagnosis, and treatment protocols for future disasters.

158 CONCLUSION Current intensive treatment protocols for localized ESFT have erased the c

159 ture this parameter may be used to determine treatment protocols for lower calyceal stones.

160 al therapeutic approaches include randomized treatment protocols for multisystem disease.

161 ic companion study (CALGB 8461) to all CALGB treatment protocols for newly diagnosed adults with acut

162 ndation for the development of risk-specific treatment protocols for patients with CDH.

163 n be used to inform novel biologically based treatment protocols for patients with medulloblastoma.

164 erapies and might aid the development of new treatment protocols for retinoic acid-resistant patients

165 Uncontrolled series of treatment protocols for severe Henoch-Schonlein purpura

166 ) are considered an integral part of current treatment protocols for the decontamination of titanium

167 Current treatment protocols for this condition are still unpredi

168 id therapy for anthrax must be considered in treatment protocols for this disease.

169 y, there is a pressing need to develop novel treatment protocols for this high-risk patient group.

170 then this may lead to selection criteria and treatment protocols for very early hypothermia in HIE at

171 pical clinical setting over a long duration, treatment protocols had marked heterogeneity, and substa

172 The same treatment protocols had no effect on AMCE cells derived

173 ration of these agents into transplant-based treatment protocols has improved outcomes.

174 ithium or ibudilast to existing chemotherapy treatment protocols has the potential to prevent chemoth

175 ma patients still exists, yet new methods of treatment protocol have been proposed for patients in tr

176 in paediatric acute lymphoblastic leukaemia treatment protocols have improved overall survival, the

177 Complex patient factors and variability in treatment protocols have made it difficult to identify,

178 of the seven patients who have completed the treatment protocol (i.e., one or if necessary a second i

179 f intravenous artesunate (2.4 mg/kg) under a treatment protocol implemented by the Centers for Diseas

180 were examined for elements of trial design, treatment protocols, important biases, and major finding

181 study to evaluate a standardized endoscopic treatment protocol in a large cohort of patients with SP

182 Implementation of a mandatory treatment protocol in May 2003.

183 rons followed by secondary assays (i.e. post-treatment protocol in organotypic hippocampal slice cult

184 and 6MP were prognostic in the setting of a treatment protocol in which all treatment was coordinate

185 study of hypothetical "static" and "dynamic" treatment protocols in a sequential multiple-assignment

186 have been used under emergency compassionate-treatment protocols in human patients.

187 ge tissues undergoing apoptosis after cancer treatment protocols in humans.

188 nurses are more likely to initiate standard treatment protocols in situations such as the one report

189 ll as create the potential for more targeted treatment protocols in various health conditions.

190 th chronic periodontitis underwent different treatment protocols, in six groups: three FMD groups and

191 lineated the current standard prevention and treatment protocols including intensive glycemic and blo

192 review highlights the need for standardized treatment protocols, including an agreed-upon standardiz

193 is an ongoing controversy on the benefits of treatment protocols, including dental lasers and photody

194 An integrated sepsis treatment protocol incorporating empirical antibiotics,

195 Contemporary, response stratified, treatment protocols incorporating dexamethasone have bee

196 e development of novel electrode designs and treatment protocols, increases in clinical success, defi

197 Treatment protocols increasingly stratify therapy accord

198 cal implementation of a comprehensive sepsis treatment protocol is feasible and is associated with ch

199 cheduling variant of the experimentally used treatment protocol is fragile (nonrobust) and (ii) disco

200 mized DELFIA procedure incorporating an acid treatment protocol is introduced for use with Eu(III)-DO

201 Our data suggest that this BM cell-based treatment protocol is safe, is well tolerated, and allow

202 eterrent to an otherwise extremely effective treatment protocol is the development in patients of loc

203 Eligibility for intensive AML treatment protocols is therefore typically based on age

204 In addition, differences in treatment protocols leave questions unanswered regarding

205 higher patient comprehension of the clinical treatment protocol, lower patient anxiety, higher patien

206 The type of graft and immune treatment protocol may influence the extent and reversib

207 Delayed treatment protocols may extend the window of opportunity

208 ng and treating physician as previously used treatment protocols may no longer provide the best patie

209 dition of the TRP-1-directed mAb TA99 to the treatment protocol mediated eradication of s.c. lesions.

210 We propose that, to the extent that this treatment protocol more closely reflects clinical exposu

211 d with various combinations of the following treatment protocols: murine CTLA4-Ig, L-6 control Ig, si

212 ly as every 4 weeks based on a structured re-treatment protocol (n = 191 eyes).

213 lantitis that were treated with an intensive treatment protocol of bi-weekly supragingival plaque rem

214 NO is a useful adjunct to the postoperative treatment protocol of heart transplant patients with pul

215 iation criteria and treated according to the treatment protocol of the network were consecutively col

216 vide insights into the development of better treatment protocols of congenital eye disorders.

217 onto two sequential series of risk-adjusted treatment protocols of the Children's Cancer Group.

218 After analyzing the treatment protocols of the SIOP Europe International Neu

219 We examined the effect of the treatment protocol on antibodies to donor HLA, third-par

220 We investigated the impact of two rapamycin treatment protocols on the major characteristics of alle

221 of the lacrimal artery or deviated from the treatment protocol (P = 0.035) and 14.3% for conventiona

222 ncephalopathy (P = 0.033), immunosuppressant treatment protocol (P = 0.041), donor age (P = 0.002), a

223 with their respective groups in the singular treatment protocol (p<.05).

224 In a review of these modified treatment protocols, parent involvement is emphasized as

225 the data available vary too much in terms of treatment protocols, patient mix and symptom severity to

226 Here we used a new treatment protocol (Pc 26.1) in 16 thalassemia patients

227 r a novel, donor bone marrow (BM) cell-based treatment protocol ("Pittsburgh protocol").

228 plementation of a hospitalwide bronchiolitis treatment protocol promoting OU-HOT would affect hospita

229 The treatment protocol recommended either the immediate oral

230 This treatment protocol reduced metabolic disturbances in the

231 Broader implementation of sepsis treatment protocols represents a potential means for enh

232 However, viable treatment protocols require balancing the efficacy of th

233 ecin-PS conjugates appear most promising for treatment protocols requiring repeated washing after sen

234 The treatment protocol resulted in durable tumor responses i

235 ion of systemic low-dose IL-2 therapy to the treatment protocol resulted in the loss of the antitumor

236 The treatment protocol results in PbS QD films exhibiting a

237 years, all quantitative parameters for both treatment protocols showed statistically significant imp

238 l quantitative parameters except PD for both treatment protocols showed statistically significant imp

239 ceived various combinations of the following treatment protocols: sirolimus, 1.5 mg/kg (3.0 mg/kg for

240 ith the use of a more comprehensive adjuvant treatment protocol (Spearman = 0.48, P < 0.001).

241 to be attributable to the increasing use of treatment protocols specific for ENKTL.

242 nical and basic research projects, including treatment protocol studies, acylcarnitine biomarker stud

243 ccurrences of deaths only in the hypotensive treatment protocols suggest that resuscitation to a targ

244 nt at 7 mo of age required a more aggressive treatment protocol than animals at 5.5 mo of age.

245 trial compared the response to a gingivitis treatment protocol that combined mechanical procedures a

246 y, we circumvent this by introducing a novel treatment protocol that enables the preparation of high-

247 ter lung transplantation (LTx) and discuss a treatment protocol that has been developed at our instit

248 get to improve macrophage function in a late treatment protocol that improves sepsis survival.

249 We evaluated a treatment protocol that included matched transfusions, b

250 equires a highly structured approach using a treatment protocol that includes five essential componen

251 Tunicamycin, administered as part of a treatment protocol that inhibited glycosylation of all e

252 We designed a comprehensive treatment protocol that reduces the frequency and the se

253 Lastly, we introduce an improved treatment protocol that uses a lower rapamycin concentra

254 linary approach will provide a comprehensive treatment protocol that will increase the long-term viab

255 produce different conclusions about optimal treatment protocols that minimize resistance.

256 The development of treatment protocols that result in a complete response t

257 ively conclude which agent is better or what treatment protocol to follow.

258 ransplants and describe the evolution of our treatment protocol to one that consists only of a brief

259 a randomized, double blind, sham controlled treatment protocol to study the effects of LFMS in a lar

260 ospective drugs in intermittent and combined treatment protocols to cure T. cruzi infection initiated

261 gan specialists and adoption of standardized treatment protocols to ensure the best possible patient

262 Here, we utilized two treatment protocols to investigate whether rapamycin, co

263 outcomes have been described as well as new treatment protocols to provide a more effective therapy

264 ubicin with daunorubicin in childhood cancer treatment protocols to reduce cardiotoxicity should be a

265 ng children enrolled in one of our leukaemia treatment protocols, Total Therapy Study XII, prompted u

266 cids in the presence of blood simplifies pre-treatment protocols towards true point-of-care diagnosti

267 ded into the following four groups, based on treatment protocols: treatment with 40 mg/kg pravastatin

268 The treatment protocol used imaginal re-living of the death,

269 Nevertheless, when following the treatment protocol used in this trial among eyes with vi

270 The prevention protocol was extended and a treatment protocol used to examine if BMP-7 was benefici

271 -6)) that were independent of the risk group treatment protocol used.

272 Treatment protocols used in this study were well tolerat

273 A standard treatment protocol using rapid interhospital transfer fo

274 On October 2012, a treatment protocol using SAED was introduced after years

275 efficacy of SAP treatment, we used a delayed treatment protocol using SAP from day 7 to 13 only, and

276 This work also suggests that standard treatment protocols using BZ and NFX may be significantl

277 The development of clinical treatment protocols usually relies on evidence-based gui

278 A 2 stage NAM treatment protocol was applied.

279 lts with LL, an intensive pediatric-like ALL treatment protocol was associated with a good response r

280 The most effective treatment protocol was identified as activated MSC co-ad

281 Beginning in August 1997, a standardized treatment protocol was initiated for patients with suspe

282 In the late treatment protocol, we administered ethyl gallate or nor

283 At the end of the treatment protocol, we assessed cardiac function using e

284 In the early treatment protocol, we infused P. aeruginosa until mean

285 Safety and feasibility of the tiered treatment protocol were confirmed.

286 d from 1970 to 1990 on two combined modality treatment protocols were identified.

287 ncer and Leukemia Group B (CALGB) front-line treatment protocols were prospectively studied for immun

288 Multiple treatment protocols were studied, including pre-ischemic

289 Four treatment protocols were tested: Chi220 monotherapy, CTL

290 e mice or from mice tolerized through either treatment protocol, were always able to prevent rejectio

291 een 2004 and 2016, who were eligible for the treatment protocol, were prospectively studied.

292 years) enrolled in a multisite research and treatment protocol, which included surgery, risk-adapted

293 his new information into the next-generation treatment protocols will unleash new challenges.

294 his is the first UK real-life study of a T&E treatment protocol with ranibizumab for exudative ARMD i

295 Novel treatment protocols with inclusion of antibodies and sma

296 in 50 HBeAg-negative patients under various treatment protocols with interferon alpha and/or nucleos

297 The development of treatment protocols with reduced toxicity and equivalent

298 e group seem superb, with histology-directed treatment protocols without radiation in both localized

299 rolonged overall survival when compared with treatment protocols without surgery (HR 7.26, 95% CI 3.4

300 component of continuation therapy in all ALL treatment protocols worldwide.